Recent Advancements on the Use of Exosomes as Drug Carriers for the Treatment of Glioblastoma.
Angela GalardiAlexander De BethlenVirginia Di PaoloSilvia LampisAngela MastronuzziAngela Di GiannatalePublished in: Life (Basel, Switzerland) (2023)
Glioblastoma (GBM) is the most common and aggressive cancer of the brain. Presently, GBM patients have a poor prognosis, and therapy primarily aims to extend the life expectancy of affected patients. The current treatment of GBM in adult cases and high-grade gliomas in the pediatric population involves a multimodal approach that includes surgical resection followed by simultaneous chemo/radiotherapy. Exosomes are nanoparticles that transport proteins and nucleic acids and play a crucial role in mediating intercellular communication. Recent evidence suggests that these microvesicles may be used as biological carriers and offer significant advantages in targeted therapy. Due to their inherent cell-targeting properties, circulation stability, and biocompatibility, exosomes are emerging as promising new carriers for drugs and biotherapeutics. Furthermore, these nanovesicles are a repository of potential diagnostic and prognostic markers. In this review, we focus on the therapeutic potentials of exosomes in nano-delivery and describe the latest evidence of their use as a therapeutic tool in GBM.
Keyphrases
- poor prognosis
- end stage renal disease
- mesenchymal stem cells
- high grade
- stem cells
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- long non coding rna
- risk assessment
- papillary thyroid
- radiation induced
- cancer therapy
- pain management
- single cell
- emergency department
- multiple sclerosis
- radiation therapy
- human health
- patient reported
- blood brain barrier